Muscarinic acetylcholine receptors (M 1 -M 5 ) regulate many key functions in the central and peripheral nervous system. Due to the lack of receptor subtype-selective ligands, however, the physiological roles of individual muscarinic receptor subtypes remain to be determined. In this study, we examined the effects of the muscarinic M 2 /M 4 receptor-preferring agonist [5R-(exo)]-6-[4-butylthio-1,2,5-thiadiazol-3-yl]-1-azabicyclo-[3.2.1]-octane (BuTAC) on serum corticosterone levels in M 2 and M 4 receptor single knockout (KO) and M 2,4 receptor double KO mice. Responses were compared with those obtained with the corresponding wild-type (WT) mice. BuTAC (0.03-0.3 mg/kg s.c.) dose dependently and significantly increased serum corticosterone concentrations in WT mice to 5-fold or greater levels compared with vehicle controls. In muscarinic M 2 and M 2,4 KO mice, however, BuTAC had no significant effect on corticosterone concentrations at doses of 0.1, 0.3, and 1 mg/kg s.c. In both WT and muscarinic M 4 KO mice increases in serum corticosterone concentrations induced by BuTAC (0.1 and 0.3 mg/kg) were not significantly different and were blocked by scopolamine. In summary, the muscarinic M 2,4 -preferring agonist BuTAC had no effect on corticosterone levels in mice lacking functional muscarinic M 2 receptors. These data suggest that the muscarinic M 2 receptor subtype mediates muscarinic agonist-induced activation of the hypothalamic-pituitary-adrenocortical axis in mice.
There are five muscarinic acetylcholine receptor subtypes, designated M 1 , M 2 , M 3 , M 4 , and M 5 , widely expressed in the central nervous system and in the periphery. Muscarinic receptors modulate the activity of many neurotransmitter systems in the brain, play a key role in memory and learning, and regulate a great number of sensory, motor, and autonomic processes. Moreover, central cholinergic receptor dysfunction has been suggested to be involved in the pathophysiology of schizophrenia (Haroutunian et al., 1994 ), Alzheimer's disease (Avery et al., 1997; Rodriguez-Puertas et al., 1997 ), Parkinson's disease (Griffiths et al., 1994; Asahina et al., 1998) , and depression (Riemann et al., 1994) . Muscarinic agonists have been reported to have antipsychotic-like activity in animal models (Bymaster et al., 1998) and schizophrenic patients (Pfeiffer and Jenney, 1957) , to improve cognitive function and psychotic-like behaviors in Alzheimer's disease (Avery et al., 1997; Bodick et al., 1997) , and to have antidepressant properties (Janowsky et al., 1972) .
Muscarinic M 1 to M 4 receptors are widely distributed throughout the brain, with most brain regions expressing several different muscarinic receptor subtypes (Levey et al., 1991) . This overlapping receptor expression pattern, along with a lack of subtype-selective muscarinic agonists and antagonists available for study, has made the functional roles for individual muscarinic receptors difficult to determine. Recently, however, mice lacking specific muscarinic receptor subtypes have been produced by gene ablation technology (Hamilton et al., 1997; Gomeza et al., 1999a,b; Yamada et al., 2001a,b) . These genetic knockout (KO) mice have been useful in assigning specific pharmacological functions to individual muscarinic receptors. For example, studies with muscarinic M 2 KO mice have shown that muscarinic M 2 receptors, which are negatively coupled to adenylate cyclase, mediate bradycardia, tremor, hypothermia, and analgesic effects (Gomeza et al., 1999a; Stengel et al., 2000; Bymaster et al., 2001; Gomeza et al., 2001 ). Mice lacking muscarinic M 4 receptors, which are also negatively coupled to adenylate cyclase, showed increased basal locomotor activity and enhanced dopamine D 1 receptor-mediated locomotor stimulation, suggesting that M 4 receptors exert inhibitory control over dopamine D 1 receptor-dependent locomotor stimulation (Gomeza et al., 1999b . Muscarinic M 4 receptors have also been shown to lack a functional role in muscarinic agonist-induced tremor and hypothermia and do not play a predominant role in muscarinic agonist-induced analgesia and salivation (Gomeza et al., 1999b; Bymaster et al., 2001 ).
Muscarinic agonists have been shown to stimulate the hypothalamic-pituitary-adrenocortical axis (HPA) axis via central corticotropin-releasing hormone release (Hedge and De Wied, 1971; Sithichoke and Marotta, 1978; Calogero et al., 1989; Bugajski et al., 1998) . The muscarinic receptor subtype mediating corticotropin-releasing hormone secretion and subsequent stimulation of the HPA axis, however, has not been established. In this study, we investigated muscarinic agonist-induced increases in serum corticosterone concentrations using muscarinic M 2 and M 4 receptor single KO and M 2, 4 receptor double KO mice and the corresponding WT control strains. Both the M 2 and M 4 receptors are selectively coupled to G proteins of the G i family that, at a biochemical level, mediate the inhibition of adenylate cyclase (Wess, 1996) . We focused on muscarinic M 2 receptors due to their high density in forebrain regions such as hypothalamus (Levy, 1993) and compared effects to another adenylate cyclase-coupled receptor, the muscarinic M 4 receptor, which also is located in rat forebrain regions (Levy, 1993; Yasuda et al., 1993) . We used the muscarinic M 2 /M 4 receptor-preferring partial agonist [5R-(exo)]-6-[4-butylthio-1,2,5-thiadiazol-3-yl]-1-azabicyclo-[3.2.1]-octane (BuTAC) (Sauerberg et al., 1998) , which has been shown to stimulate corticosterone release in rats (S. K. Hemrick-Luecke, unpublished data), has low parasympathomimetic side effects, and reduced potential for stress-induced changes in animal models (Shannon et al., 1999) . Scopolamine, a nonselective muscarinic antagonist, was used to block the increases in corticoid levels produced by BuTAC. We also tested agents known to stimulate the HPA axis via activation of central serotonin and dopamine receptors to demonstrate normal function of the HPA axis in muscarinic M 2 , M 4 , and M 2,4 receptor KO mice.
Materials and Methods
The generation of muscarinic M 2 receptor KO mice (genetic background: 129/J1 ϫ CF1; 50%/50%) and muscarinic M 4 receptor knockout mice (129/SvEv ϫ CF1; 50%/50%) has been described previously by Gomeza et al. (1999a,b) . M 2,4 receptor double KO mice [129/J1 (25%) ϫ 129SvEv (25%) ϫ CF1 (50%)] were generated by intermating homozygous M 2 and M 4 receptor KO mice (J. Gomeza and J. Wess, unpublished data) . In all experiments, age-matched WT mice of the matching genetic background were used as control animals. Mouse genotyping was carried out by polymerase chain reaction analysis of mouse-tail DNA. Immunoprecipitation studies with subtype-selective antibodies confirmed the lack of M 2 and M 4 receptor protein in the homozygous (Ϫ/Ϫ) M 2 and M 4 receptor knockout mice, respectively. Moreover, immunoprecipitation studies indicated that the loss of M 2 or M 4 receptors did not lead to changed expression levels of the remaining muscarinic subtypes (Gomeza et al., 1999a,b) .
Age-matched male mice (4 -6 weeks old) weighing 20 to 25 g were used for all studies. Mouse colonies were amplified by Taconic Farms (Germantown, NY). Mice were housed five per cage in an environmentally controlled room at 22°C with lights on from 7:00 AM to 7:00 PM and were acclimatized for 1 week before experimentation. Food and water were freely available at all times. Animal use protocols were reviewed and approved by institutional animal care and use committees accredited by Assessment and Accreditation Association of Laboratory Animal Care International. BuTAC and pergolide were provided by Lilly Research Laboratories (Indianapolis, IN) and dissolved in 0.01 N HCl for injection. Scopolamine hydrochloride was obtained from Sigma-Aldrich (St. Louis, MO) and dissolved in sterile H 2 O for injection. Quipazine [2-(1-piperazinyl) quinoline maleate] was purchased from Miles Laboratories (Elkhart, IN) and dissolved in sterile H 2 O for injection. 8-Hydroxy-2-dipropylaminotetralin (8-OH-DPAT) was purchased from Sigma/RBI (Natick, MA) and dissolved in 0.01 N HCl for injection. All mice were administered drugs or vehicles at 5 ml/kg by routes indicated. Mice were sacrificed by decapitation (between 9:00 and 11:00 AM) 1 h after administration of BuTAC, pergolide, 8-OH-DPAT, or quipazine. Trunk blood was collected and allowed to clot, and serum was obtained by centrifugation and stored frozen at Ϫ70°C before assay. Serum corticosterone concentrations were measured by radioimmunoassay (corticosterone 3 H-RIA kit; ICN Biomedicals, Costa Mesa, CA). Samples were diluted according to kit instructions and analyzed in duplicate. Analysis of variance, followed by Tukey's honestly significant difference test post hoc, was performed with significant differences at P Յ 0.05. Fifty percent effective doses (ED 50 ) were calculated using bestfit linear regression analyses.
Results
Preliminary data showed that BuTAC, a muscarinic M 2,4 -preferring partial agonist, administered at a dose of 0.1 mg/kg s.c., significantly increased serum corticosterone concentrations in WT mice as well as in muscarinic M 4 KO mice at 1 h, but did not affect levels of corticoids in muscarinic M 2 KO mice (data not shown). Because doses of BuTAC lower than 0.1 mg/kg s.c. would be expected to be ineffective on corticoid levels in M 2 and M 2,4 KO mice, higher doses were administered, whereas doses of BuTAC administered to WT and M 4 KO mice were chosen to show a dose-dependent effect on corticoid levels.
The effects of BuTAC on serum corticosterone concentrations in muscarinic M 2 receptor KO mice and corresponding WT control mice are shown in Fig. 1A . One hour after BuTAC administration, corticosterone concentrations were dose dependently increased in WT mice at doses of 0.03, 0.1, and 0.3 mg/kg s.c. In muscarinic M 2 KO mice, BuTAC had no effect on corticosterone concentrations at doses up to 1 mg/kg s.c. In contrast, Fig. 1B shows that BuTAC produced nearly identical increases in serum corticosterone concentrations in WT compared with M 4 KO mice, with significant increases occurring at 0.03, 0.1, and 0.3 mg/kg. In M 2,4 double KO mice (Fig.  1C) , doses of BuTAC as high as 1 mg/kg had no effect on corticoid levels, whereas BuTAC significantly increased corticosterone concentrations in WT mice.
The effect of the nonselective muscarinic receptor antagonist scopolamine (1 mg/kg) on the increase in corticoid levels produced by BuTAC (0.1 mg/kg) in muscarinic M 4 KO mice and corresponding WT controls is shown in Table 1 . The differences in basal levels of corticosterone in vehicle-treated mice are due to normal variability in corticoid levels, because we observed no consistent trend for increased levels in WT compared with muscarinic M 4 KO mice. Scopolamine alone had no significant effect on corticoid levels, but prevented the 5-fold increase in corticoid levels in WT mice and the 10-fold increase in muscarinic M 4 KO mice produced by BuTAC.
The effects of BuTAC and compounds known to increase corticoid levels by other receptor mechanisms were compared in WT and KO mice (Fig. 2) . As described above, BuTAC (0.1 mg/kg) significantly increased corticosterone concentrations in M 4 KO mice and in all WT mice, but had no effect on corticoid levels in M 2 KO and M 2,4 KO mice. The dopamine D 1 /D 2 receptor agonist pergolide (0.3 mg/kg i.p.) produced significant increases in corticoid levels in M 2 KO mice, M 4 KO mice, and M 2,4 KO mice similar to increases observed in the corresponding WT control mice. Likewise, the serotonin (5-HT) 1A receptor agonist 8-OH-DPAT (0.3 mg/kg s.c.) and the 5-HT 2A receptor agonist quipazine (10 mg/kg s.c.) produced similar increases in corticosterone concentrations in M 2 KO mice, M 4 KO mice, M 2,4 KO mice, and corresponding WT control mice.
Discussion
The partial muscarinic agonist BuTAC was used to determine muscarinic receptor-mediated effects on corticoid levels in muscarinic KO and WT mice, primarily due to its reduced potential to cause stress-induced changes in corticoid levels due to parasympathetic side effects (Shannon et al., 1999) . BuTAC also increases serum corticosterone levels in rats (S. K. Hemrick-Luecke, unpublished observation) and mice at doses shown to be pharmacologically active (Sauerberg et al., 1998; Rasmussen et al., 2001) . BuTAC is a partial agonist at muscarinic M 2 receptors (K i ϭ 0.4 nM) and M 4 receptors (K i ϭ 0.6 nM), and an antagonist at muscarinic M 1 receptors (K i ϭ 0.6 nM), M 3 receptors (K i ϭ 0.2 nM) and M 5 receptors (K i ϭ 0.7 nM) in cloned cell lines (Sauerberg et al., 1998) . In radioligand binding assays BuTAC at 1 M did not appreciably interact with other nonmuscarinic neuronal receptors or neurotransmitter transporters with the exception of slight affinity for ␣-receptors in vitro (Sauerberg et al., 1998) . At doses similar to those increasing corticoid levels in WT mice, BuTAC inhibited conditioned avoidance responding in rats without response failure or catalepsy and displayed large separations between antidopaminergic doses and doses that produce parasympathomimetic effects in mice (Sauerberg et al., 1998; Shannon et al., 1999) .
BuTAC produced dose-dependent increases in serum corticosterone concentrations with similar potency and magni- tude in all strains of WT control mice and muscarinic M 4 receptor KO mice. This BuTAC-induced increase in corticoid levels in M 4 KO and WT mice was blocked by scopolamine, a nonselective antagonist with high affinity for muscarinic receptor subtypes (Bolden et al., 1992) , indicating that stimulation of the HPA axis by BuTAC was due to muscarinic receptor activation. In muscarinic M 2 receptor KO mice and in M 2,4 receptor KO mice, however, BuTAC had no significant effect on corticoid levels at doses 10 to 30 times higher than doses required to significantly increase corticosterone concentrations in WT control mice. The muscarinic M 2 receptor subtype thus regulates corticoid release in mice. The location of these receptors, however, cannot be determined from these data. Further studies are needed to elucidate whether muscarinic agonist-induced corticoid release is mediated by centrally located muscarinic M 2 receptors that stimulate corticotropin-releasing hormone-containing neurons in the hypothalamus, resulting in corticotropin-releasing factor, adrenocorticotropin hormone, and corticosterone release or by peripheral stimulation of muscarinic M 2 receptors located on the adrenal cortex. Nonetheless, stimulation of the HPA axis is mediated by muscarinic M 2 receptors in mice.
We also show that the dopamine D 2 receptor agonist pergolide, the 5-HT 1A receptor agonist 8-OH-DPAT, and the 5-HT 2A receptor agonist quipazine all produced increases in corticosterone concentrations in M 2 , M 4 , and M 2,4 KO mice, similar to the increases observed in corresponding WT control mice. This suggests that the HPA axis is able to function normally in muscarinic M 2 , M 4 , and M 2,4 receptor KO mice with regard to dopaminergic and serotonergic receptor agonist-induced stimulation. Of particular interest is that the 5-HT 1A receptor agonist 8-OH-DPAT produced an increase in corticosterone concentrations in the muscarinic M 2 and M 2,4 receptor KO mice similar to WT mice. 5-HT 1A receptors, like muscarinic M 2 and M 4 receptors, are negatively coupled to adenylate cyclase. Similar increases in 8-OH-DPAT-induced corticoid levels in WT mice and muscarinic KO mice indicate an intact adenylate cyclase transduction system. Thus, the only abnormality observed on corticoid levels is the lack of effect by the muscarinic M 2,4 receptor-preferring agonist BuTAC on corticoid levels in mice lacking functional muscarinic M 2 receptors.
Because ligands able to clearly distinguish between muscarinic receptor subtypes are not available, stimulation of the HPA axis may provide a means to evaluate muscarinic M 2 receptor activation in animals and humans. Stimulation of the HPA axis by muscarinic agents would provide a measure of muscarinic M 2 receptor agonist activity, thus allowing for development of drugs with fewer side effects. Muscarinic M 2 receptors have been implicated in the regulation of many central and peripheral functions, including control of heart rate and contraction of smooth muscle (Gomeza et al., 1999a Stengel et al., 2000; Bymaster et al., 2001 ). In the central nervous system, muscarinic M 2 receptors can function as inhibitory autoreceptors (Zhang et al., 1999) implicated in parasympathetic effects, movement control, and changes in body temperature and pain sensitivity (Gomeza et al., 1999a; Bymaster et al., 2001) .
Evidence exists that cholinergic mechanisms may have a regulatory effect in affective disorders. The cholinergic-adrenergic hypothesis of mania and depression (Janowsky et , and quipazine (10 mg/kg s.c.) were administered to groups of mice (n ϭ 5-10) 1 h before serum was collected. Data are expressed as the percentage of basal levels for vehicle-treated mice (basal levels correspond to 100%). Corticosterone concentrations in control mice were 52.4 Ϯ 10.3 ng/ml for WT and 64.8 Ϯ 20.8 ng/ml for M 2 KO, 81.4 Ϯ 25.2 ng/ml for WT and 76.0 Ϯ 21.0 ng/ml for M 4 KO, and 72.2 Ϯ 27.8 ng/ml for WT and 60.7 Ϯ 30.6 ng/ml for M 2,4 mice. ‫,ء‬ P Յ 0.05 compared with control corticoid levels.
al., 1972) states that hypercholinergic (or hypoadrenergic) activity results in depression, whereas hypocholinergic (or hyperadrenergic) activity results in mania. Cholinergic muscarinic mechanisms have been implicated in preclinical (Hassey and Hannin, 1991; Overstreet et al., 1986 Overstreet et al., , 1998 and clinical (Dilsaver, 1986; Janowsky and Overstreet, 1995) models of depression. Furthermore, cholinomimetics and direct-acting cholinergic agonists increase levels of corticotropin-releasing hormone, adrenocorticotropin hormone, and cortisol (Risch et al., 1983; Janowsky et al., 1986; Suda et al., 1987; Calogero et al., 1989) , although evidence linking stimulation of the HPA axis to cholinergic activity in humans is lacking. Nonetheless, depression is associated with hyperactivity of the HPA axis (Nemeroff, 1996; Arborelius et al., 1999) , and development of muscarinic acetylcholine M 2 receptor antagonists might be effective in the treatment of depression.
In conclusion, our data show that the muscarinic M 2 receptor subtype mediates muscarinic agonist-induced stimulation of corticosterone release, whereas muscarinic M 4 receptors do not seem to be involved in this activity.
